-

$undefined

N/A

(N/A)

vTv Therapeutics NASDAQ:VTVT vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment of type 1 diabetes and inflammatory disorders, including psoriasis. vTv's development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary disease (COPD), renal disease, and primary mitochondrial myopathy.

Location: 3980 Premier Dr, Suite 310, North Carolina, 27265, US | Website: www.vtvtherapeutics.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

14.23M

Cash

41.66M

Avg Qtr Burn

-5.849M

Short % of Float

2.49%

Insider Ownership

39.02%

Institutional Own.

22.89%

Qtr Updated

09/30/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Cadisegliatin (TTP399) (GLP-1R agonists) Details Diabetes, Type 1 diabetes	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
HPP737 (PDE4 inhibitor) Details Psoriasis, Skin disease/disorder	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Cadisegliatin (TTP399) (GLP-1R agonists) Details Diabetes, Type 2 diabetes	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TTP273 (Oral GLP-1R) Details Diabetes, Type 2 diabetes, Cystic fibrosis	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TTP488 (Azeliragon) (RAGE) Details Frontotemporal dementia with C9orf72 mutation, Dementia, Alzheimer's disease, Neurological disorder	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.